Cancer Testing Screening Market Report: Trends, Forecast and Competitive Analysis to 2030

Cancer Testing Screening Trends and Forecast

The future of the global cancer testing screening market looks promising with opportunities in the hospital, clinic, diagnostic center, and research institute applications. The global cancer testing screening market is expected to reach an estimated $214.2 billion by 2030 with a CAGR of 5.1% from 2024 to 2030. The major drivers for this market are rising prevalence of cancer cases, growing need for accurate diagnostic tools and early detection methods, and increasing preference for liquid biopsy.

A more than 150-page report is developed to help in your business decisions.

Cancer Testing Screening by Segment

The study includes a forecast for the global cancer testing screening by technique, cancer type, application, end use, and region.

Cancer Testing Screening Market by Technique [Shipment Analysis by Value from 2018 to 2030]:

• Imaging
• Biopsy
• Genomic and Molecular Tests
• Next Generation Sequencing
• RT-PCR
• Microarrays
• Biomarker Testing
• Others

Cancer Testing Screening Market by Cancer Type [Shipment Analysis by Value from 2018 to 2030]:

• Respiratory System Cancer
• Leukemia
• Myeloma and Lymphoma
• Skin Cancer
• Abdominal/Digestive System Cancer
• Urinary System Cancer
• Endocrine System Cancer
• Breast Cancer
• Others

Cancer Testing Screening Market by Application [Shipment Analysis by Value from 2018 to 2030]:

• Hospitals
• Clinics
• Diagnostic Centers
• Research Institutes
• Others

Cancer Testing Screening Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

• Patients
• Healthcare Providers
• Diagnostic Laboratories
• Research Institutes
• Pharmaceutical Companies

Cancer Testing Screening Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

List of Cancer Testing Screening Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies cancer testing screening companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the cancer testing screening companies profiled in this report include-

• Diasorin
• Immunodiagnostic Systems
• Epigenomics
• Quest Diagnostics
• F. Hoffmann-La Roche
• VolitionRX
• Abbott Laboratories
• QIAGEN
• Siemens Healthineers

Cancer Testing Screening Market Insights

Lucintel forecasts that biopsy is expected to witness highest growth over the forecast period due to its great accuracy in the diagnosis of cancer.

Hospital is expected to witness highest growth over the forecast perioddue to rising patients preference for this facility for their treatment given to the availibility of well established infrastructure and presence of medical expertise.

North America is expected to witness highest growth over the forecast period due to constant increase in instances of prostate and lung cancer cases in the region.

Features of the Global Cancer Testing Screening Market

Market Size Estimates: Cancer testing screening market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Cancer testing screening market by various segments, such as by technique, cancer type, application, end use and region in terms of($B).

Regional Analysis: Cancer testing screening market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different techniques, cancer types, applications, end uses, and region.s for the cancer testing screening market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the cancer testing screening market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1. What is the cancer testing screening market size?

Answer: The global cancer testing screening market is expected to reach an estimated $214.2 billion by 2030.

Q.2. What is the growth forecast for cancer testing screening market?

Answer: The global cancer testing screening market is expected to grow with a CAGR of 5.1% from 2024 to 2030.

Q.3. What are the major drivers influencing the growth of the cancer testing screening market?

Answer: The major drivers for this market are rising prevalence of cancer cases, growing need for accurate diagnostic tools and early detection methods, and increasing preference for liquid biopsy.

Q.4. What are the major segments for cancer testing screening market?

Answer: The future of the cancer testing screening market looks promising with opportunities in the hospital, clinic, diagnostic center, and research institute applications.

Q.5. Who are the key cancer testing screening market companies?

Answer: Some of the key cancer testing screening companies are as follows:

• DiaSorin
• Immunodiagnostic Systems
• Epigenomics
• Quest Diagnostics
• F. Hoffmann-La Roche
• VolitionRX
• Abbott Laboratories
• QIAGEN
• Siemens Healthineers

Q.6. Which cancer testing screening market segment will be the largest in future?

Answer: Lucintel forecasts that biopsy is expected to witness highest growth over the forecast period due to its great accuracy in the diagnosis of cancer.

Q.7. In cancer testing screening market, which region is expected to be the largest in next 5 years?

Answer: North America is expected to witness highest growth over the forecast period due to constant increase in instances of prostate and lung cancer cases in the region.

Q.8. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the cancer testing screening market by technique (imaging, biopsy, genomic and molecular tests, next generation sequencing, RT-PCR, microarrays, biomarker testing, and others), cancer type (respiratory system cancer, leukemia, myeloma and lymphoma, skin cancer, abdominal/digestive system cancer, urinary system cancer, endocrine system cancer, breast cancer, and others), application (hospitals, clinics, diagnostic centers, research institutes, and others), end use (patients, healthcare providers, diagnostic laboratories, research institutes, and pharmaceutical companies), and region. (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?